Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Chimerix Inc (CMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7977
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. It also develops active compounds against malaria, influenza A and B, brincidofovir for smallpox, dengue virus and tuberculosis, brincidofovir and adenovirus, among others. Chimerix’s lipid antiviral conjugate technology is used to modify a drug molecule order that it mimics a naturally occurring phospholipid metabolite. The company provides research and development services in the areas of CMV and BK virus, influenza, norovirus, and viruses that have significant global impact and there are currently no effective treatments, antivirals are associated with known toxicities such as bone marrow suppression and renal impairment. Chimerix is headquartered in Durham, North Carolina, the US.

Chimerix Inc (CMRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Chimerix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chimerix Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 10
Equity Offering 12
Chimerix to Raise USD75 Million in Public Offering of Shares 12
Chimerix Completes Exercise of Over-Allotment Option for Public Offering of Shares for USD22.5 Million 13
Chimerix Raises USD122 Million in Public Offering of Shares 15
Chimerix Raises USD119.4 Million in Public Offering of Shares 17
Chimerix Completes IPO For US$118 Million 19
Chimerix Inc – Key Competitors 21
Chimerix Inc – Key Employees 22
Chimerix Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 08, 2018: Chimerix announces second quarter 2018 financial results 24
May 07, 2018: Chimerix Reports First Quarter 2018 Financial Results 26
Mar 01, 2018: Chimerix Announces Fourth Quarter and Full Year 2017 Financial Results 28
Nov 08, 2017: Chimerix Announces Third Quarter 2017 Financial Results 30
Aug 07, 2017: Chimerix Announces Second Quarter 2017 Financial Results 32
May 09, 2017: Chimerix Announces First Quarter 2017 Financial Results 33
Mar 02, 2017: Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results 35
Corporate Communications 37
Mar 29, 2018: Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors 37
Product News 38
02/22/2017: Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings 38
Clinical Trials 39
Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Chimerix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Chimerix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 10
Chimerix to Raise USD75 Million in Public Offering of Shares 12
Chimerix Completes Exercise of Over-Allotment Option for Public Offering of Shares for USD22.5 Million 13
Chimerix Raises USD122 Million in Public Offering of Shares 15
Chimerix Raises USD119.4 Million in Public Offering of Shares 17
Chimerix Completes IPO For US$118 Million 19
Chimerix Inc, Key Competitors 21
Chimerix Inc, Key Employees 22
Chimerix Inc, Subsidiaries 23

List of Figures
Chimerix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • A&D Company Ltd (7745):企業の財務・戦略的SWOT分析
    Summary A&D Company Ltd (A&D Company) is a medical equipment company that manufactures, designs, develops, and distributes advanced measuring, controlling, monitoring, and testing instruments. The company’s products include powertrain testing systems, digital analog converter, DSP platform, model ba …
  • Enerplus Corp (ERF):石油・ガス:M&Aディール及び事業提携情報
    Summary Enerplus Corp (Enerplus), formerly Enerplus Resources Fund is an oil and gas company that offers exploration and development services. The company provides exploration and development of natural resource properties for the production of crude oil, light and heavy oil, natural gas, shallow ga …
  • Redbiotec AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Redbiotec AG (Redbiotec) is a biopharmaceutical company that develops prophylactic vaccines, which target various virus associated diseases. The company produces multi component virus like particles and other protein assemblies through its rePAX coexpression technology. It is developing prod …
  • Marquard & Bahls AG:企業の戦略・SWOT・財務分析
    Marquard & Bahls AG - Strategy, SWOT and Corporate Finance Report Summary Marquard & Bahls AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Achema AB:企業の戦略的SWOT分析
    Achema AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Lowe’s Companies, Inc.:戦略・SWOT・企業財務分析
    Lowe's Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Lowe's Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Juhl Energy Inc:企業の戦略的SWOT分析
    Juhl Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Chang Hwa Commercial Bank, Ltd.:企業の戦略・SWOT・財務情報
    Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cinkarna Celje d.d. Celje (CICG):企業の財務・戦略的SWOT分析
    Cinkarna Celje d.d. Celje (CICG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Galderma SA:企業の戦略的SWOT分析
    Galderma SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Tauron Polska Energia SA:企業の発電所・SWOT分析2018
    Tauron Polska Energia SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • CIRCOR Aerospace Products Group:企業の戦略・SWOT・財務情報
    CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report Summary CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Chiesi Farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, …
  • Avista Corporation (AVA):電力:M&Aディール及び事業提携情報
    Summary Avista Corporation (Avista) is an electric and natural gas utility. The company produces, transmits, and distributes electricity; and supplies natural gas on retail and wholesale basis. It sources electricity from its facilities and contracted hydroelectric, thermal and wind generation facil …
  • Eurus Energy Holdings Corp:電力:M&Aディール及び事業提携情報
    Summary Eurus Energy Holdings Corp (Eurus Energy), a subsidiary of Toyota Tsusho Corporation, is a renewable energy company that generates power through various renewable sources such as wind and solar photovoltaic. The company's services include location survey, wind or sunlight study, basic design …
  • Allan Myers Inc:企業の戦略・SWOT・財務情報
    Allan Myers Inc - Strategy, SWOT and Corporate Finance Report Summary Allan Myers Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Acorda Therapeutics Inc (ACOR):企業の財務・戦略的SWOT分析
    Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Chronos Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Chronos Therapeutics Ltd (Chronos) is a research company that offers drug discovery and development services. The company offers research and development, drug discovery, lead optimization, preclinical efficacy, IND enabling, screening, pipeline development and clinical trial services. Its p …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Auris Medical Holding Ltd (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding Ltd (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆